Lymphoma clinical trials in Washington
13 studies for Lymphoma are looking for participants at sites in Washington.
Cities in Washington
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- Seattle Children s Hospital, Seattle
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Nov 9, 2026 · NCT05237986A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07015242A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Swedish Cancer Institute, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06084936A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07221500A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 30, 2026 · NCT06520098Collection of Tissue Samples for Cancer Research
- Fred Hutchinson, Seattle
RecruitingObservational study
2 Months · All sexes · Updated Oct 27, 2026 · NCT00900198A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Fred Hutch Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06528301CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- University of Washington Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT03328078A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776DALY II USA/ MB-CART2019.1 for DLBCL
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.